Biotech Startups
9,875 companies tagged Biotech, with their investors and founders.
Flyttr operates a biosecurity platform that develops and deploys countermeasures against pest threats, combining autonomous pest monitoring systems, AI-powered decision-support, and biological interventions such as engineered Aedes aegypti and Wolbachia. It serves national governments, agricultural authorities, industry partners and field operators across public health, agriculture, and livestock domains.
3 investors
Ozette runs a vertically integrated, AI-enabled lab and platform that generates high-dimensional spectral cytometry data and analyzes it to produce reproducible biomarker endpoints for clinical trials. It serves biopharma clinical development teams, discovery/R&D groups, and academic labs, operating under a validated (GCLP-compliant) quality system.
3 investors
Pacifico Biolabs produces mycelium-based meat alternatives (branded Viando), starting with a chicken alternative made from fermented fungi, for food manufacturers and food service chains. It uses steel fermentation bioreactors to make its "mycomeat" as a B2B ingredient that integrates into existing meat supply chains and cooking processes.
3 investors
Panakeia develops software for biomarker profiling aimed at making precision diagnostics faster and instrument-free, to inform cancer diagnosis, treatment, and drug development. Its solutions target clinicians and researchers working in precision medicine and oncology.
3 investors
PanTher develops targeted cancer therapeutics that deliver drugs directly to tumor sites at high concentrations over extended periods, aiming to improve clinical outcomes while reducing side effects. The platform is designed to be applicable across multiple therapeutic types for oncology treatment.
3 investors
Paradox Immuno develops a platform for discovering therapies targeting protein misfolding diseases, leveraging proprietary research and lead identification technology to address rare conditions with no existing treatments.
3 investors
Parallel Fluidics manufactures custom microfluidic devices in production-grade thermoplastics, offering quotes from uploaded CAD files and delivery in as few as three days. It serves researchers and engineers in fields such as biomedical and aerospace, using its Transition Molding process to support rapid prototyping and scale-up to hundreds of devices per month.
3 investors
Paratus Sciences is a drug discovery company that uses AI-powered methods to identify first-in-class medicines by studying evolutionary traits, targeting serious diseases where current therapies are inadequate. The company combines computational discovery with drug development expertise to create new therapeutic programs.
3 investors
Passkey operates Locksmith, a computational platform that uses human genetics, biology, and pharmacology to identify synergistic drug combinations from approved and late-stage drugs, allowing existing assets to be repurposed for new indications. The company partners with pharmaceutical firms to map clinic-ready combinations that bypass preclinical development and move directly to human trials, initially targeting complex diseases such as cancer.
3 investors
Pathalys Pharma is a biotechnology company developing and improving therapeutic treatments for patients with chronic kidney disease.
3 investors
PathogenDx provides molecular pathogen detection assays using proprietary D3 Technology for rapid, multiplexed identification of bacterial, fungal, and viral pathogens in food, agricultural, clinical, and environmental samples.
3 investors
Pathos applies AI, biological modeling, and a large collection of multimodal oncology patient data to develop cancer drugs and accelerate clinical development. It operates the PathOS platform with engines for asset selection, clinical trial execution, and an oncology foundation model.
3 investors
Pearl Diagnostics develops diagnostic assays for detecting fungal infections, including a urine-based test for Aspergillus. The company operates in the medical diagnostics and biotech industry.
3 investors
Pelage develops regenerative medicines for hair loss based on stem cell biology, with a lead candidate (PP405) that is a topical small-molecule drug designed to reactivate dormant hair follicle stem cells. It targets conditions including androgenetic alopecia, drug-induced alopecia, and telogen effluvium, and is currently in clinical trials.
3 investors
Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2Ξ± for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.
3 investors
PentaBind designs programmable aptamersβsmall RNA/DNA molecules with sub-nanomolar binding affinityβfor continuous sensing and diagnostics applications (e.g., monitoring hormones and biomarkers) and targeted therapeutics in oncology and drug delivery. The platform reduces aptamer design cycles from months to ~22 days and delivers application-ready assets rather than just binders.
3 investors
Permanence Bio is a biotech company developing therapies aimed at cancer prevention by protecting the genome from damage, drawing on aging and DNA repair research. It works to discover cancer-preventing compounds and advance lead compounds from mechanism of action through IND-enabling studies and into the clinic.
3 investors
PetaGene develops PetaSuite, Linux software that losslessly compresses genomic data files (BAM and FASTQ.gz) by 60-90% while allowing tools to access files in their original format via on-the-fly decompression, both on-premises and in the cloud. It serves genomics research organizations, hospitals, and life sciences institutions to reduce storage costs and data transfer times.
3 investors
Petal is developing an incisionless surgery platform using Millisecond Pulse Histotripsy, a form of focused therapeutic ultrasound that breaks down targeted diseased tissue without incisions, heat, or trauma. The system is designed for patients, clinicians, and hospitals as an alternative to conventional and robotic surgery.
3 investors
Pharmacelera develops computational chemistry software and services for drug discovery, using proprietary 3D molecular field descriptors, quantum mechanics, and AI to screen ultra-large chemical libraries and identify novel, synthesizable compounds. It serves small biotech companies, big pharma R&D departments, public research institutions, and CROs across stages from target identification to lead optimization.
3 investors
Pharmaron is a contract research and manufacturing organization providing drug development and manufacturing services to pharmaceutical and biotech companies.
3 investors
PharmEnable applies AI to small molecule drug discovery, focusing on challenging and data-sparse biological targets that traditional methods struggle to address. The company develops first- and best-in-class therapies and originated as a spin-out from the University of Cambridge.
3 investors
PhaseV provides AI/ML-driven software for designing and optimizing clinical trials, including trial simulation, adaptive design, patient subgroup identification, and early endpoint detection. It serves biopharma sponsors and contract research organizations (CROs) in the clinical development and drug trial industry.
3 investors
Phathom Pharmaceuticals is a pharmaceutical company that develops and markets prescription treatments, including VOQUEZNA (vonoprazan) for gastrointestinal conditions, in the U.S. market.
3 investors